News & Analysis on Clinical Trial Services & Contract Research And Development
By Melissa Fassbender
- Last updated on
Derek Ansel, who joins Synteract as director of rare and orphan disease development, was previously a clinical strategy lead at the Center for Rare Diseases and a co-founder of the gene therapy working group at a CRO.
Ansel is an ACRP member and holds a Certified Clinical Research Associate (CCRA) credential. He also is an IRB member at the Thomas Jefferson University in Philadelphia and a member of Cochrane, a non-profit organization that promotes evidence-based decision making in health care.
“I’m thrilled to join Synteract where I’m committed to developing and operationalizing global strategies for rare disease trials,” Ansel told us. “My goal is to make Synteract the rare disease service provider of choice by leveraging our deep knowledge within advanced therapies and providing our clients with innovative solutions to streamline their rare disease studies.”